Revisiting G3BP1 as a RasGAP binding protein: sensitization of tumor cells to chemotherapy by the RasGAP 317-326 sequence does not involve G3BP1

A. Annibaldi, A. Dousse, S. Martin, J. Tazi, C. Widmann

To cite this version:
A. Annibaldi, A. Dousse, S. Martin, J. Tazi, C. Widmann. Revisiting G3BP1 as a RasGAP binding protein: sensitization of tumor cells to chemotherapy by the RasGAP 317-326 sequence does not involve G3BP1. PLoS ONE, Public Library of Science, 2011, 6 (12), pp.e29024. 10.1371/journal.pone.0029024. hal-02193305

HAL Id: hal-02193305
https://hal.archives-ouvertes.fr/hal-02193305
Submitted on 26 May 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Revisiting G3BP1 as a RasGAP Binding Protein: Sensitization of Tumor Cells to Chemotherapy by the RasGAP 317–326 Sequence Does Not Involve G3BP1

Alessandro Annibaldi¹, Aline Dousse¹, Sophie Martin², Jamal Tazi², Christian Widmann¹*

1 Department of Physiology, University of Lausanne, Lausanne, Switzerland, 2 Institut de Génétique Moléculaire de Montpellier UMR 5535, IFR 122, Centre National de Recherche Scientifique, Montpellier, France

Abstract

RasGAP is a multifunctional protein that controls Ras activity and that is found in chromosomal passenger complexes. It also negatively or positively regulates apoptosis depending on the extent of its cleavage by caspase-3. RasGAP has been reported to bind to G3BP1 (RasGAP SH3-domain-binding protein 1), a protein regulating mRNA stability and stress granule formation. The region of RasGAP (amino acids 317–326) thought to bind to G3BP1 corresponds exactly to the sequence within fragment N2, a caspase-3-generated fragment of RasGAP, that mediates sensitization of tumor cells to genotoxins. While assessing the contribution of G3BP1 in the anti-cancer function of a cell-permeable peptide containing the 317–326 sequence of RasGAP (TAT-RasGAP317–326), we found that, in conditions where G3BP1 and RasGAP bind to known partners, no interaction between G3BP1 and RasGAP could be detected. TAT-RasGAP317–326 did not modulate binding of G3BP1 to USP10, stress granule formation or c-myc mRNA levels. Finally, TAT-RasGAP317–326 was able to sensitize G3BP1 knock-out cells to cisplatin-induced apoptosis. Collectively these results indicate that G3BP1 and its putative RasGAP binding region have no functional influence on each other. Importantly, our data provide arguments against G3BP1 being a genuine RasGAP-binding partner. Hence, G3BP1-mediated signaling may not involve RasGAP.

Introduction

There is an ongoing need to improve current anti-tumor regimens to reduce the rate of death due to cancer. In this context, we discovered earlier that the caspase-3-generated RasGAP N-terminal fragment (RasGAP158–455), called N2, was able to selectively sensitize cancer cells, but not healthy cells, to genotoxin-induced apoptosis [1]. RasGAP amino acids 317 to 326 within fragment N2 were found to carry this sensitizing activity [2]. A cell-permeable peptide containing this sequence (the so-called TAT-RasGAP317–326 peptide) was then generated [2]. This peptide potently enhances the efficacy of genotoxins to selectively kill cancer cells, both in vitro and in vivo [3] and in vitro settings. TAT-RasGAP317–326 does not induce apoptosis by itself making it a pure sensitizer compound [2–4]. The understanding of its mode of action is of particular relevance in the context of the mechanisms allowing cancer cells to resist apoptosis. It is known that TAT-RasGAP317–326 favors genotoxin-induced mitochondrial outer membrane depolarization (MOMP) and caspase-3 activation [5]. The RasGAP-derived peptide requires a functional p53/PUMA axis to induce its genotoxin-sensitization effect [5]. However, this might only reflect the fact that genotoxins require the p53/PUMA axis to optimally kill cancer cells [6,7]. At present, the direct molecular target(s) of TAT-RasGAP317–326 are unknown and the cellular events underlying its sensitizing properties are only minimally understood.

GAP SH3 Binding Protein 1 (G3BP1) is one of the molecules described to interact with RasGAP. This was first reported by Parker et al. in 1996 [8] who identified and cloned a molecule able to bind to the SH3 domain of RasGAP. Incidentally, this interaction only took place in serum-stimulated cells. The binding between RasGAP and G3BP1 could be prevented by a peptide corresponding to sequence 317–326 found within the RasGAP SH3 domain. These data were corroborated by two other reports showing that G3BP1 binds to RasGAP in proliferating cells [9] and that the G3BP1 domain responsible for these binding was the nuclear transfer factor 2 (NTF2)-like domain, located at its N-terminus [10]. This domain was also described to mediate the binding of the yeast orthologue of G3BP1 (Bre5) to the Ubp3 deubiquitinating enzyme [11]. G3BP1 seems not to be a substrate of USP10, the Ubp3 mammalian orthologue, but it appears to inhibit the capacity of USP10 to cleave ubiquitin chains [12]. The C-terminal portion of G3BP1 contains two canonical RNA recognition motifs (RRMs) indicating that G3BP1 has RNA-binding capacities. Indeed G3BP1 was reported to co-immuno-
precipitate with mRNAs and to bind to and cleave the 3’ untranslated region (3’UTR) of the c-myc mRNA in vivo [9]. Interestingly, the endoribonuclease activity of G3BP1 is governed by its phosphorylation status. In proliferating cells, when G3BP1 is hypo-phosphorylated, it loses its ability to cleave mRNA whereas in quiescent cells, when it is hyper-phosphorylated, it does cleave mRNAs [9]. This observation suggested a possible role of G3BP1 in coupling extra-cellular stimuli to mRNA stability. This hypothesis is supported by the finding that G3BP1 is implicated in stress granule (SG) assembly [13]. SGs correspond to cytoplasmic loci where mRNAs are stored during stress conditions and where the decision to degrade or convert them into translationally active mRNA protein complexes (mRNPs) is taken once the stress has subsided [14–16]. Formation of stress granules in cells may inhibit apoptosis [17].

The observation that G3BP1 binds to RasGAP on the very same sequence that mediates the tumor sensitizing activity of fragment N2 and the fact that G3BP1 is over-expressed in some cancer cells made G3BP1 a good candidate for the TAT-RasGAP[317–326] peptide ability to lower the resistance specifically in cancer cells. We therefore investigated whether the known functions attributed to G3BP1 could be modulated by TAT-RasGAP[317–326] and whether G3BP1 was required for the peptide to sensitize tumor cells to genotoxin-induced apoptosis.

Materials and Methods

Cell lines and transfection

U2OS (LGC Promochem; ATCC n° HTB-96), HCT116 [18], HEK293T [19], HeLa cells (LGC Promochem; ATCC n° CCL-2), and CCL39 cells (LGC Promochem; ATCC n° CCL-39), as well as wild-type and G3BP1 knock-out mouse embryonic fibroblasts (MEFs) [20] were maintained in DMEM (Invitrogen reference n°61965) containing 10% fetal calf serum (GIBCO/ BRL reference n°10270-106, lot n°41Q6001K) at 37°C and 5% CO2. HEK293T and U2OS cells were transfected using the calcium/phosphate precipitation procedure [22,21].

Buffers

The composition of phosphate buffered saline (PBS) is 116 mM NaCl, 10.4 mM Na2HPO4, 3.2 mM KH2PO4 (pH 7.4). The Stag lysis buffer is made of 50 mM Hepes pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA pH 8.0, 10% glycerol, 1% Triton X-100, and is supplemented with one tablet of EDTA-free inhibitor (Roche) per 50 ml. The composition of sample buffer 2X is 25 mM 2-amino-2-(hydroxyethyl)-1,3-propanediol (Tris) HCl pH 6.5, 10% glycerol, 6% SDS, 0.02% of bromophenol blue and 100 mM freshly added dithiothreitol (DTT). The 1% Triton X-100 lysis buffer is made of 20 mM Hepes pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM MgCl2, 1 mM EGTA and 1 mM NaVO4 supplemented with one tablet of EDTA-free inhibitor (Roche) per 50 ml. The composition of sample buffer 5X is 250 mM Tris-Cl pH 7, 10% SDS, 30% glycerol, 5% β-mercaptoethanol. Tris buffer saline (TBS) is made of 20 mM Tris base, 130 mM NaCl, pH 7.6.

Antibodies

The monoclonal antibody specific for the hemagglutinin (HA) tag was purchased as ascites from BabCo (reference n’MMS-101R). This antibody was adsorbed on HeLa cell lysates to decrease non-specific binding as described previously [22]. Mouse anti-human G3BP1 was from BD Transduction Laboratories (reference n°611127). The rabbit polyclonal anti human TH-1 antibody was from Santa Cruz (reference n’sc-20237) The anti S-Protein HRP-conjugated antibody was from Novagen (reference n°60047). The anti-OCT antibody was from Upstate (reference n’06-332). The polyclonal rabbit anti-c-Myc antibody was from Cell Signaling (reference n°9402). The polyclonal rabbit anti-RasGAP antibody directed at the Src homology (SH) domains of RasGAP was from Enzo Life Sciences (reference n’ALX-210-860-R100). The monoclonal mouse anti-SV40 large T antigen was from BD Pharmingen (reference n°554149). The rabbit anti-USP10 antibody was provided by Dr. Olivier Staub (University of Lausanne, Switzerland). The monoclonal mouse anti-V5 antibody was from Invitrogen (reference n°46-0705). Secondary antibodies were donkey anti-mouse fluorescein-conjugated antibody and donkey anti-rabbit Cy3-conjugated antibody (Jackson ImmunoResearch, reference n°715-095-1507 and 711-163-152, respectively).

Plasmids

The extension _dn3_ indicates that the backbone plasmid is pcDNA3 (#1) (Invitrogen). _S-tag_ corresponds to the first 15 amino acids of the S-peptide of RNase A (amino acids 1–15 of RNase A). The S-tag is bind with high affinity to the S protein (amino acid 21–124 of RNase A) [23,24]. TRIP-PKG-1RESNEO-WHIV (#350) is a lentiviral vector bearing the neomycine resistance. The pEGFP-C1 plasmid (#6) encodes the green fluorescent protein and is from Clonetech. The hG3BP1.dn3 plasmid (#322) encodes human G3BP1 [8]. HA-RhoGAP préc (#196) encodes the HA-tagged form of rat p190RhoGAP. The 6His-Stag-mUSP10.dn3 plasmid (#464) encoding the pollyhistidine- and S-tagged form of mouse USP10 was described earlier [25]. HA-hRasGAP.dn3 (#118), previously called HA-RasGAP.dn3 (#22), encodes the HA-tagged form of human RasGAP. HA-hRasGAP[18–455].dn3 (#145), previously called HA-N2.dn3 (#22), encodes the HA-tagged fragment of fragment N2. HA-hRasGAP[1–455](D157A).dn3 (#352), previously called N-D157A.dn3 (#22), encodes the HA-tagged caspase-3-resistant form of fragment N. V5-hRasGAP[3–455](D157A).dn3 (#350) encodes a V5-tagged version of the caspase-3-resistant form of fragment N that lacks its first two methionine residues (to prevent potential internal translation events). It was constructed by PCR amplifying HA-hRasGAP[1–455](D157A).dn3 with oligonucleotide #559 [AA (feeder sequences) GGTACC (KpnI site) GCCACC (Kozak sequence) ATG GGA AAA CGA ATG CAA AAT CGA CTA CGA GCC GAC AGT ACA (V5 tag) CGG GCC GAG GCC GGC AGT (sequences complementary to RasGAP from third amino acid on; nucleotides 124–133 of the human RasGAP mRNA; entry M23379)] and oligonucleotide #560 [GCA ACG AAG TGG GCA GTT TG (sequences lying within the human RasGAP mRNA downstream of the SacII site; nucleotides 489–469 of human RasGAP mRNA; entry M23379)]. The resulting 427 bp PCR fragment was cut with KpnI and SacII and subcloned in HA-hRasGAP[1–455](D157A).dn3 opened with the same enzymes. V5-hRasGAP[3–1931].dn3 (#686) encodes a V5-tagged version of human RasGAP that lacks its first two methionine residues (to prevent potential internal translation events). It was made by subcloning the SpeI/SacII fragment of V5-hRasGAP[3–455](D157A).dn3 into HA-hRasGAP.dn3 opened with the same enzymes. HA-hG3BP1.dn3 (#541) encodes an HA-tagged version of human G3BP1. It was produced by PCR amplifying the hG3BP1.dn3 plasmid with oligonucleotide #501 [AAA (feeder sequences), GGATCC (BamHI site),...
GGATCC (Kozak sequence), ATG GGC TAC CCG TAC GAC GTG CCG GAC TAC GCT TCT (HA tag), ATG GTG ATG GAG AAC CCT ATG (nucleotides 172–191 of the human G3BP1 mRNA; NCBI entry NM_005754) and oligonucleotide #502 [TTTTT (feeder sequences), GGTGAC (Sal site) TCT ACT GCC GTG GCG CAA GCC CCC TTC (nucleotides 1573–1547 of the human G3BP1 mRNA; NCBI entry NM_005754)]. The resulting 1453 bp fragment was blunted with T4 DNA polymerase (Promega reference n° M421A), digested with BamHI and subcloned into pcDNA3 opened with BamHI and EcoRV.

**Stag-GFP.dn3** (#647) encodes a T-tagged form of the green fluorescent protein (GFP). It was generated by PCR amplifying plasmid pEGFP-C1 with oligonucleotide #686 [AAAAA (feeder), GGATCC (BamH I site), GCCACC (Kozak sequence), ATG AAA GAA ACC GCT GCT GCT AAA TTC GAA GCG CAG CAC ATG GAC AGC (S-tag), ATG GTG ATG GAG AAC CCT ATG (nucleotides 172–191 of the human G3BP1 mRNA; NCBI entry NM_005754)] and oligonucleotide #687 [AAA (feeder), CGG TCG ACT GAA GAA TTC GAA CGC CAG (Kozak position), ATG GCG (start codon and alanine codon), TA (first 21 base pairs of fragment N2) and oligonucleotide GAG AAG CCT AG (nucleotides 172–191 of the human G3BP1 mRNA; NCBI entry NM_005754)] and oligonucleotide GAG AAG CCT AG (nucleotides 172–191 of the human G3BP1 mRNA; NCBI entry NM_005754) and oligonucleotide #502.

**TTC GAA GC** (nucleotides of pEGFP-C1 surrounding the EcoRI site; underlined). The amplified PCR fragment was then digested with EcoRI and subcloned into pcDNA3 opened with the same enzymes.

**Stag-hRasGAP[158–455].dn3** (#754) encodes the S-tagged form of fragment N2 and was constructed by PCR amplifying plasmid HA-hRasGAP[158–455].dn3 with oligonucleotide #796 [TAAGCAG (feeder sequence), AAGCTT HindIII (Hi)IIIII, GCTGAG (Xho I) CCCAC (Kozak sequence); the last nucleotide of the XhoI recognition site provides the G at the Kozak position], ATG GCC (start codon and alanine codon), AAA GAA ACC GCT GCT GCT AAA TTC GAA GCG CAG CAC ATG GAC AGC (S-tag) TCT GTG GAT GGA CCA GAA GA (nucleotides 1018–999 of pcDNA3)]. The resulting 1027-base pairs PCR fragment was then digested with HindIII and subcloned in HA-hRasGAP[158–455].dn3 opened with the same enzymes.

**SV40LargeTantigen.pBABE-puro** (#731) encodes the SV40 large T antigen (Adgene; plasmid 13970). **SV40LargeTantigen.lti-neo** (#738) similarly encodes the large T antigen but in a lenti viral expression vector. It was constructed by subcloning the BamHI 2187 base pairs fragment of SV40LargeTantigen.pBABE-puro into TRIP-PGK-ires-neo-HIV opened with the same enzyme.

**Non-target.pLoKo-puro** (#584) corresponds to a pLoKo.1-puro lentiviral expression vector containing a shRNA construct that does not target human and mouse genes (Sigma Aldrich, reference n° SHC002). **shRNA-hG3BP1.pLoKo-puro** (#641) encodes a shRNA targeting a sequence within the 3′UTR of the human G3BP1 mRNA (nucleotides 1976–1997 of entry NM_005754). It was purchased from Sigma Aldrich.

**6xHis-hRasGAP[279–343].pET28** (#544) encodes a histidine-tagged form of the SH3 domain of RasGAP. It was constructed as follows. HA-hRasGAP[no 3′UTR],dn3 (#424) [1] was amplified by PCR using oligonucleotide #505 [AT (feeder) CATATG (Nde I site) AGA AGG CCG GTG GTA CGA GCT AT (human RasGAP; nucleotides 959–978 of NCBI entry M23579)] and oligonucleotide #506 [AT (feeder) GGCGGCGC (Not I site) CTA (stop codon)] CGG GCC CAG CTC CTC TCG TAC TA (human RasGAP; nucleotides 1143–1122 of NCBI entry M23579)]. The amplified fragment was cut with the NdeI and Not I restriction enzymes and the resulting 192 base pair fragment was subcloned into vector pET-28a(+)(#343) opened with the same enzymes. A PCR-generated A to G silent mutation was found at position 1129 (numbering based on NCBI entry M23579) in 6xHis-hRasGAP[279–343],dn3. **His-TAT-GFP** (#130) encodes a fusion protein made of a stretch of 6 histidine residues, the TAT sequence, and GFP.

**S-TAG pull down**

Two millions U2OS cells were seeded in a six-well plate and the next day transfected using the calcium/phosphate precipitation procedure. After an additional 24-hour period, cells were lysed in Stag lysis buffer and 1 mg of the lysates were incubated with 1 μl of biotinylated S-protein (Novagen; reference n° 69218) for 3 hours at 4°C. Thirty μl of streptavidin beads (GE Healthcare Bio-Sciences; reference n° 17-5113-01) were then added to the samples and the incubation resumed for an additional 1-hour period. Pull down complexes were then washed 3 times with PBS, 1% NP40 and solubilized in 30 μl of sample buffer 2X.

**Immunoprecipitation**

One million cells (either CCL39 or U2OS) were seeded in 10-cm plates and 24 hours later the cells were lysed in 1% Triton X-100 lysis buffer. Alternatively, one million HEK 293T cells were seeded in 10-cm plates and 24 hours later they were transfected using the calcium/phosphate precipitation procedure. After an additional 24-hour period they were lysed in RIPA-like lysis buffer. Protein content was measured by Bradford. Seven hundreds μg of total protein were immunoprecipitated with 1 μg of the anti-RasGAP antibody overnight at 4°C with rotation at 9 rpm. Twenty μl of G protein sarcose beads (GE Healthcare; reference n° 17-0618-01) were then added for an additional 2 hour period. Immunocomplexes were then washed three times with washing buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40) and solubilized in 30 μl of sample buffer 2X. Samples were heated 10 minutes at 95°C before loading.

**Quantitative PCR**

RNA was isolated with the “High Pure RNA isolation kit” (Roche; reference n° 11828665001) according to the manufacturer’s instruction. The RNA was then reverse-transcribed with the “Transcriptor high fidelity cDNA kit” (Roche; reference n° 05 284 001) as per the manufacturer’s instruction. Quantitative PCR assays were carried out on a real-time PCR detection system (iQ5; Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad; reference n° 170–8862) using primers at a 500 nM concentration. The sequences of the e-myc specific primers were GGA CGA CGA GAC CTT CAT CAA (oligonucleotide #728, nucleotide 926–946 of e-myc mRNA, NCBI entry: NM_002467.3) and CCA GCT TCT CTG AGA CGA GCT T (oligonucleotide #729, nucleotide 996–1017 of e-myc mRNA, NCBI entry: NM_002467.3). The 18S ribosomal RNA was used for normalization. The primers used to amplify this RNA were GGA ATT ATT CCC CAT GAA CG (oligonucleotide #774, nucleotide 1617–1636, NCBI entry: NR_003278.1) and GGC CTC ACT GAA CCA TCC AA (oligonucleotide #775, nucleotide 1720–1739, NCBI entry: NR_003278.1).

**Western blotting**

Two hundred thousand cells were seeded in six-well plates and 24 hours later they were subjected to the treatments indicated in the figures after which they were lysed in sample buffer 5X. Proteins were quantitated using the Bradford method. Equal amounts of proteins were subjected to SDS-PAGE and then transferred onto a nitrocellulose membrane (Biorad; reference n° 162 0115). The membranes were blocked with TBS containing 0.1% Tween-20 and 5% non-fat milk and incubated overnight at 4°C with the indicated primary antibodies used at 1:1000 dilution. Blots were then washed with TBS-Tween 0.1%, incubated with the appropriate secondary antibody (1:5000 dilution) 1 hour at room temperature and subsequently visualized with the Odyssey...
infrared imaging system (LICOR Biosciences, Bad Homburg, Germany).

Lentivirus

Recombinant lentiviruses were produced as described [26]. Briefly, HEK293T cells were co-transfected using the calcium phosphate DNA precipitation method [21] with 50 μg of the lentiviral vector (TRIP-PGKATGm-MCS-WHV) containing the cDNA of interest (i.e. G3BP1 shRNA), 2.5 μg of the envelope protein-coding plasmid (pMD.G), and 7.5 μg of the packaging construct (pCMVDR8.91). Two days after transfection, the virus-containing medium was harvested. Infection of the cells was performed as follows. Hexadimethrine bromide (Polybrene; Sigma; reference n° 52495) was added to cells cultured in six-well plates at a final concentration of 5 μg/ml followed by the addition of the lentivirus. The plates were then centrifuged 45 minutes at 800 g and placed 24 hours at 37°C in a 5% CO2 humidified atmosphere. The medium was then replaced with fresh medium, and the cells were further cultured for an additional 48 hour period before being used in specific experiments.

Immunocytochemistry

Two hundred thousand cells were seeded in six-well plates containing glass coverslips and 24 hours later they were transfected with the calcium/phosphate precipitation procedure. One day post-transfection, the cells were fixed as follows (all steps were performed at room temperature). The cells on coverslips were washed with 4 ml of PBS, fixed with 3 ml PBS, 3% formaldehyde, 3% sucrose for 10 minutes, washed thrice with PBS, permeabilized with 2 ml of PBS, 0.2% Triton X-100 for 10 min, washed thrice with PBS, and incubated 30 minutes with 3 ml of filtered serum-containing culture medium. After three additional PBS washes, the coverslips were incubated for 1 hour with the primary antibody diluted in DMEM, 10% newborn calf serum. The coverslips were washed 3 times over 30 minutes in PBS and then incubated 1 hour with a 1/100 dilution of labeled secondary antibodies in DMEM, 10% newborn calf serum. The coverslips were washed 3 more times in PBS and labeled when indicated with 10 μg/ml Hoechst 33342 (Molecular Probe) before being mounted (Vectorsheld mounting medium, Vector laboratories Inc). Confocal images were captured with a Leica SP5 AOBS confocal microscope.

Determination of G3BP1 nuclear content

Confocal images were converted to tif format and opened with Adobe Photoshop Elements 5.0 software. Pictures of Hoechst-stained cells were used to create masks of the nuclei that were then overlaid on the pictures of G3BP1-stained cells in order to delimitate the nuclear area. The nuclear G3BP1 signal image was then opened using the ImageJ software (1.34n version) and the nuclear signal was quantitated. Similarly, the total G3BP1 staining was quantitated for each picture with the ImageJ software (in this case the cell contours were manually drawn). The nuclear G3BP1 signal was calculated as the percentage of the total G3BP1 cell staining.

Peptides

TAT and TAT-RasGAP317–326 are retro-inverso peptides (i.e. synthesized with D-amino acids in the opposite direction compared to the natural sequence). The TAT moiety corresponds to amino acids 48–57 of the HIV TAT protein (RRRQRRKKKRG) and the RasGAP317–326 moiety corresponds to amino acids 317–326 of the human RasGAP protein (DTRLNTVWMW). These two moieties are separated by two glycine linker residues in the TAT-RasGAP317–326 peptide. The peptides were synthesized at the Department of Biochemistry, University of Lausanne, Switzerland, using Fmoc technology, purified by HPLC and tested by mass spectrometry.

Protein production and purification

Plasmids coding for recombinant proteins were expressed in BL21 E. coli. Bacteria were grown overnight in lysogeny broth (LB) medium (casein enzymatic hydrolysatate 10 g/l, yeast extract 5 g/l, NaCl 170 mEq/l, pH 7.5). The induction of the recombinant proteins was performed by the addition of 0.1 mM isopropyl-beta-thiogalactoside (IPTG) to the culture medium when it reached on optical density at 600 nm of 0.6. After 4 hours of induction, the cells were harvested and resuspended in 5 ml Buffer A [HEPES 50 mM, magnesium acetate 200 mM, NaCl 500 mM, Triton X-100 0.1%, lysoyzme 2 mg/ml, 0.5% β-mercaptoethanol and 10 μg/ml DNaseI, supplemented with one tablet of EDTA-free inhibitor (Roche) per 50 ml]. In order to fully lyse the cells, the suspension was sonicated (Heisner DmBH sonicator, 0.9 cycles per second, 80% amplitude) 4 times 30 seconds on ice and then centrifuged 20 minutes at 9’000 g at 4°C. A sample of the lysate was kept to verify the induction of the protein. GST-tagged proteins were then purified. The glutathione-sepharose beads (Amersham Pharmacia Biotech; reference n°17-0756-01) were washed 3 times with PBS and then incubated with the lysate at 4°C with rotation (Labinco rotary mixer, 12 rpm). The beads were washed thrice with PBS. To elute the recombinant protein, the beads were incubated with 500 μl of glutathione elution buffer (50 mM Tris pH 8, 10 mM reduced glutathione [Sigma reference n° G-4251]) for 15 minutes at 4°C with rotation. The beads were then pulled down at 4’000 g and the supernatant was collected. Histidine-N2 recombinant proteins were produced as described above, except that nickel beads were used (Ni-NTA agarose, Qiagen; reference n°1000632) instead of glutathione-Sepharose beads. The elution step was then performed with buffer A (see above) supplemented with 25 mM imidazole (Sigma reference n° I2399).

Statistics

All the statistical analyses were done with Microsoft Excel (XP edition) using the unpaired Student’s t test. Significance is indicated by an asterisk when P<0.05/n, where P is the probability derived from the t test analysis and n is the number of comparisons done (Bonferroni correction).

In silico protein docking assays

The G3BP1 NT2F domain structure (PDB entry #2Q90) was first refined using Maestro v90211 in order to complete and refine the loops. Molecular dynamics simulations were conducted using the AMBER 11.0 force field from the NAMD 2.7 package. Using AmberTools 11.0, the resulting system was solvated in a rectangular box extending 12 Å around the molecule using TIP3P water molecules. Sodium and chloride ions were added to neutralize the system. Five thousand steps of energy minimization were applied on the entire system. Following minimization, the system was equilibrated with 5’000 steps of water-only molecular dynamics at 150°K, the system was heated from 0 to 300°K for 100 picoseconds. After heating, a 5 nanosecond production simulation was conducted with a 1 picosecond time step at a pressure of 1 bar and a temperature of 300°K. The RasGAP SH3 domain (PDB entry #2JO5) was optimized using the same method. The docking was performed using Hex 5.1 standard parameters. The 150 best poses out of 10’000 were collected and analyzed. The resulting complexes were ranked according to their free interactions energy. The same docking method was applied to
the SH3 domain of RasGAP and sequence 190–233 of UBP3, the USP10 yeast orthologue (PDB entry #2QIY).

Results

No evidence for a RasGAP-G3BP1 interaction

Previous data indicated that G3BP1 binds to a discrete sequence of RasGAP within its SH3 domain that corresponds to amino acids 317–326 of the protein [8]. As fragment N2 bears this SH3 domain, we postulated that it should allow fragment N2 to bind to G3BP1. However, Figure 1 shows that in HEK 293T cells fragment N2 failed to pull down G3BP1 in conditions where USP10, a deubiquitinating enzyme known to interact with G3BP1 [12], did. It could be argued that the 317–326 sequence is not accessible on fragment N2 while it would be exposed on the parental full-length protein. We therefore assessed if an interaction between RasGAP and G3BP1 could be demonstrated. Figure 2 indicates that RasGAP could not co-immunoprecipitate with G3BP1, while it did with p190 RhoGAP, a known RasGAP binding partner [27,28]. G3BP1 binding to RasGAP has been reported in the CCL39 (Chinese hamsters lung fibroblast) cell line [9]. Conceivably, this interaction could be cell-type specific. Therefore, we immunoprecipitated RasGAP from both CCL39 cells and U2OS cells. Figure 3 shows that endogenous RasGAP protein interacted with p190 RhoGAP in both cell lines. In these conditions, no interaction could be detected between RasGAP and G3BP1.

TAT-RasGAP317–326 does not affect the binding of G3BP1 to USP10

It might be argued that the G3BP1-RasGAP interaction is transient and difficult to detect by the techniques we have used here. This interaction might nevertheless occur and one could hypothesize that TAT-RasGAP317–326 sensitizes tumor cells by modulating G3BP1 functions by either inhibiting the binding of RasGAP to G3BP1 or by mimicking the binding of RasGAP to G3BP1. One of the reported functions of G3BP1 is to bind to and inhibit USP10 [12]. We therefore assessed if TAT-RasGAP317–326 could prevent the binding of G3BP1 to this protein. Figure 4 shows that the interaction of G3BP1 to USP10 was unaffected by TAT-RasGAP317–326, indicating that the peptide does not affect the inhibitory function of G3BP1 on USP10.

TAT-RasGAP317–326 does not impair stress granule formation

In response to environmental stress (i.e. heat and oxidative conditions) eukaryotic cells stop the translation of constitutive

![Figure 1](image1.png)

**Figure 1. G3BP1 does not bind to RasGAP-derived fragment N2.** Lysates (1 mg) from HEK293T cells that had been transfected with the indicated plasmids were subjected to S-TAG pull-down. Pulled-down complexes were then analyzed by Western blotting using an HA-specific antibody. In parallel, 50 μg of total cell lysates were subjected to Western blot analysis using antibodies recognizing HA or the S-TAG.

doi:10.1371/journal.pone.0029024.g001
expressed mRNAs that are then routed to phase-dense cytoplasmic granules called stress granules (SGs). Many RNA-binding proteins participate in SG assembly including G3BP1, which together with TIA-1, is a SG marker [16]. An attractive hypothesis was that TAT-RasGAP317–326 mediates its sensitization effect by inhibiting the capacity of G3BP1 to participate in SG formation when cells are subjected to cytotoxic stresses. Therefore we tested if cisplatin was able to induce SG formation in U2OS cells and if TAT-RasGAP317–326 could impair this stress-induced response. As shown in Figure 5A, formation of SGs after treatment with arsenite was observed, but cisplatin did not induce SG assembly. Consequently, it is unlikely that the ability of TAT-RasGAP317–326 to sensitize U2OS cells to genotoxic-induces apoptosis relies on an effect on SGs. Nevertheless, to assess whether TAT-RasGAP317–326 in conditions where SGs are efficiently induced, modulates their assembly, U2OS cells were pre-incubated with TAT-RasGAP317–326 and then incubated with arsenite. Figure 5B-C shows that the peptide did not affect the number of SG per cell or the number of cells exhibiting SGs. To directly evaluate whether TAT-RasGAP317–326 affects SG formation induced by G3BP1, U2OS cells...
were transfected with a GFP-tagged form of G3BP1 and incubated or not with the RasGAP-derived peptide. In this case again, the presence of TAT-RasGAP317–326 did not alter the formation of SGs (Figure 5D–E). Altogether, these results show, not only that genotoxins do not induce SG formation, but also that TAT-RasGAP317–326 does not affect the ability of G3BP1 to mediate the formation of SGs.

TAT-RasGAP317–326 does not sensitize cancer cells through the modulation of c-myc mRNA levels

The endoribonuclease activity of G3BP1 was first reported by its ability to cleave the 3′ untranslated region (UTR) of the c-myc transcript [9,29]. This transcription factor regulates the expression of hundreds of gene controlling many cellular functions including cell survival and cell death [30]. It is an oncogene (one of the first to have been characterized actually) that is deregulated in many cancer types [31]. It plays a role in apoptosis by modulating proteins belonging to the Bcl-2 family, such as the pro-apoptotic BH3 only protein Bim [32,33]. The 3′ UTR of the c-myc mRNA regulates its stability but how it does so is unclear. There are reports indicating that the 3′ UTR favors c-myc mRNA decay [34,35], while another one provides indirect evidence that the 3′ UTR contributes to c-myc mRNA stabilization [29]. If TAT-RasGAP317–326 modulates the ability of G3BP1 to cleave the c-myc mRNA it could affect the sensitivity of cells to apoptosis, in particular if c-Myc protein levels are increased because this can lead to cancer cell apoptosis, potentially via induction of Bim expression [36,37]. We therefore checked if TAT-RasGAP317–326 modulated c-myc mRNA levels and whether it affected c-Myc and Bim protein expression. Figure 6 shows that TAT-RasGAP317–326 did not modulate c-myc mRNA or c-Myc protein levels. Similarly, Bim expression was not affected by the peptide (Figure 6B). The levels of c-Myc and Bim were efficiently decreased by Actinomycin D, a transcription inhibitor, indicating that the experimental conditions used in the figure allow detecting down-modulation of c-Myc and Bim. Finally, G3BP1 protein levels did not appear to be affected by TAT-RasGAP317–326 but an effect of the peptide on the transcription or translation of G3BP1 cannot be ruled out as the half-life of G3BP1 is considerably longer than c-Myc or Bim (Figure 6B). Collectively these results do not support the possibility that TAT-RasGAP317–326 modulates the endoribonuclease activity of G3BP1 to mediate its tumor sensitization property.

TAT-RasGAP317–326 does not affect G3BP1 subcellular location

Another possibility we wanted to explore concerned G3BP1 localization. It was reported that in quiescent MEFs, G3BP1 relocates to the nucleus and that this relocalization modulates its phosphorylation status and endoribonuclease activity [29]. Specifically, when G3BP1 translocates to the nucleus, it becomes phosphorylated on serine 149 and it functions as an active endoribonuclease whereas in proliferating cells, possibly in association with RasGAP, it is dephosphorylated and loses its ability to cleave RNAs [29]. Therefore we assessed whether TAT-RasGAP317–326 could alter the sub-cellular location of G3BP1. In HeLa cells, three-dimensional reconstructions of confocal sections indicated that G3BP1 was mainly located on a flat section of the cytoplasm and was absent in areas directly above or below the nucleus (egg-on-a-plate configuration) (Figure 7A). This permitted quantitation of the nuclear G3BP1-specific signal to be performed on conventional epifluorescence images (Figure 7B), which revealed that 15–20% of G3BP1 was localized in the nucleus (Figure 7C). This nuclear location was not affected by the RasGAP-derived peptide however, indicating that the mechanism by which TAT-RasGAP317–326 sensitizes tumor cells to genotoxin-induced apoptosis does not rely on modulation of the nuclear G3BP1 content.

**Figure 4. TAT-RasGAP317-326 does not affect the binding of G3BP1 to USP10.** HEK293T cells were transfected with the indicated plasmids. Eight hours later, they were treated with the indicated concentrations of TAT-RasGAP317-326 for an additional 20 hour period at which time they were lysed. Lysates (1 mg) were subjected to S-TAG pull-down. Pulled-down complexes were analyzed by Western blotting using HA- and S-TAG specific antibodies. In parallel 50 μg of total cell lysates were subjected to Western blotting analysis using the same antibodies.

doi:10.1371/journal.pone.0029024.g004
Figure 5. TAT-RasGAP<sub>317–326</sub> does not affect G3BP1-induced SG formation. A. U2OS cells were left untreated or incubated with 15 μM cisplatin, 20 μM TAT-RasGAP<sub>317–326</sub>, or a combination of the two compounds for 22 hours. Alternatively, the cells were treated with 200 μM arsenite for 2 hours. The cells were then processed for immunofluorescence analysis using TIA-1- and G3BP1-specific antibodies. Nuclei were stained with Hoechst 33342. Images were taken with a fluorescent microscope (Nikon Eclipse 90i). Scale bar: 20 μm for the first 4 columns, 5 μm for the last.
G3BP1 ablation does not abolish TAT-RasGAP317–326-mediated sensitization of cancer cells to cisplatin

The evidence provided so far indicates that G3BP1 is not a (strong) RasGAP or fragment N2 binding partner and that TAT-RasGAP317–326 does not modulate any of the known G3BP1 functions. To unequivocally determine whether G3BP1 is needed for TAT-RasGAP317–326-mediated tumor sensitization, we used tumor cells in which G3BP1 was silenced and transformed MEFs from G3BP1 knock-out mice. Silencing G3BP1 using shRNA directed at the 3’ UTR of its mRNA resulted in 90% reduction in G3BP1 levels in U2OS cells (Figure 8A–B). This however did not prevent TAT-RasGAP317–326 from sensitizing the cells to cisplatin-induced death (Figure 8C). Earlier work has demonstrated that TAT-RasGAP317–326 does not sensitize non-cancer cells to cisplatin-induced apoptosis [2]. MEFs, which are non-cancer cells, were indeed not experiencing more cisplatin-induced death in presence of the peptide (Figure 8F). It is however possible to transform MEFs with the SV40 large T antigen [38]. We therefore expressed the large T antigen in MEFs via lentiviral infection (Figure 8D) and, as expected, this rendered them sensitive to the peptide (Figure 8G). G3BP1 is therefore dispensable for TAT-RasGAP317–326 to mediate its genotoxin-sensitizing effect on cancer cells.

Discussion

The tumor-sensitizing activity of fragment N2 towards genotoxin-induced apoptosis resides in a 10 amino acid stretch corresponding to amino acids 317–326 of RasGAP [2]. This peptidic sequence fused to a cell-permeable peptide (the so-called TAT-RasGAP317–326 peptide) is indeed capable of favoring the death of several tumor cell lines to various genotoxins [2]. Amino acids 317–326 of RasGAP correspond exactly to the sequence reported to mediate the binding of RasGAP to G3BP1 [8]. G3BP1 is a protein regulating mRNA stability, stress granule formation, and other cellular functions (reviewed in [39]). Formation of stress granules in cells has been reported to inhibit apoptosis [17]. Additionally, G3BP1 is over-expressed in certain tumors such as breast cancers [40]. As G3BP1 binds to amino acid 317–326 of RasGAP, an attractive hypothesis to explain how TAT-RasGAP317–326 sensitizes specifically tumor cells to genotoxin-induced death was that the peptide inhibits the ability of G3BP1 to form stress granule and consequently, as stress granules may exert anti-apoptotic properties [16], decreases the resistance of cancer cells towards apoptosis. This hypothesis would predict that cells lacking G3BP1 would not be sensitized by TAT-RasGAP317–326. The evidence reported in the present study demonstrates that this hypothesis is incorrect. First, genotoxins did not induce the formation of stress granules in cancer cells. Formation of stress granules cannot therefore represent a protective mechanism against genotoxins in these cells. Second, TAT-RasGAP317–326 did not modulate stress granules in conditions known to induce their formation (e.g. in the presence of arsenite). Third, the peptide efficiently sensitizes tumor cells lacking G3BP1 to genotoxin-induced death. It can therefore be unequivocally concluded that G3BP1 plays no role in the anti-tumor activity of TAT-RasGAP317–326.

The non-implication of G3BP1 in the function of TAT-RasGAP317–326 led us to reassess the reported interactions of G3BP1 with RasGAP. The RasGAP-G3BP1 interaction was first mediated its genotoxin-sensitizing effect on cancer cells.

Discussion

The evidence provided so far indicates that G3BP1 is not a (strong) RasGAP or fragment N2 binding partner and that TAT-RasGAP317–326 does not modulate any of the known G3BP1 functions. To unequivocally determine whether G3BP1 is needed for TAT-RasGAP317–326-mediated tumor sensitization, we used tumor cells in which G3BP1 was silenced and transformed MEFs from G3BP1 knock-out mice. Silencing G3BP1 using shRNA directed at the 3’ UTR of its mRNA resulted in 90% reduction in G3BP1 levels in U2OS cells (Figure 8A–B). This however did not prevent TAT-RasGAP317–326 from sensitizing the cells to cisplatin-induced death (Figure 8C). Earlier work has demonstrated that TAT-RasGAP317–326 does not sensitize non-cancer cells to cisplatin-induced apoptosis [2]. MEFs, which are non-cancer cells, were indeed not experiencing more cisplatin-induced death in presence of the peptide (Figure 8F). It is however possible to transform MEFs with the SV40 large T antigen [38]. We therefore expressed the large T antigen in MEFs via lentiviral infection (Figure 8D) and, as expected, this rendered them sensitive to the peptide (Figure 8G). G3BP1 is therefore dispensable for TAT-RasGAP317–326 to mediate its genotoxin-sensitizing effect on cancer cells.

Discussion

The evidence provided so far indicates that G3BP1 is not a (strong) RasGAP or fragment N2 binding partner and that TAT-RasGAP317–326 does not modulate any of the known G3BP1 functions. To unequivocally determine whether G3BP1 is needed for TAT-RasGAP317–326-mediated tumor sensitization, we used tumor cells in which G3BP1 was silenced and transformed MEFs from G3BP1 knock-out mice. Silencing G3BP1 using shRNA directed at the 3’ UTR of its mRNA resulted in 90% reduction in G3BP1 levels in U2OS cells (Figure 8A–B). This however did not prevent TAT-RasGAP317–326 from sensitizing the cells to cisplatin-induced death (Figure 8C). Earlier work has demonstrated that TAT-RasGAP317–326 does not sensitize non-cancer cells to cisplatin-induced apoptosis [2]. MEFs, which are non-cancer cells, were indeed not experiencing more cisplatin-induced death in presence of the peptide (Figure 8F). It is however possible to transform MEFs with the SV40 large T antigen [38]. We therefore expressed the large T antigen in MEFs via lentiviral infection (Figure 8D) and, as expected, this rendered them sensitive to the peptide (Figure 8G). G3BP1 is therefore dispensable for TAT-RasGAP317–326 to mediate its genotoxin-sensitizing effect on cancer cells.

Discussion

The evidence provided so far indicates that G3BP1 is not a (strong) RasGAP or fragment N2 binding partner and that TAT-RasGAP317–326 does not modulate any of the known G3BP1 functions. To unequivocally determine whether G3BP1 is needed for TAT-RasGAP317–326-mediated tumor sensitization, we used tumor cells in which G3BP1 was silenced and transformed MEFs from G3BP1 knock-out mice. Silencing G3BP1 using shRNA directed at the 3’ UTR of its mRNA resulted in 90% reduction in G3BP1 levels in U2OS cells (Figure 8A–B). This however did not prevent TAT-RasGAP317–326 from sensitizing the cells to cisplatin-induced death (Figure 8C). Earlier work has demonstrated that TAT-RasGAP317–326 does not sensitize non-cancer cells to cisplatin-induced apoptosis [2]. MEFs, which are non-cancer cells, were indeed not experiencing more cisplatin-induced death in presence of the peptide (Figure 8F). It is however possible to transform MEFs with the SV40 large T antigen [38]. We therefore expressed the large T antigen in MEFs via lentiviral infection (Figure 8D) and, as expected, this rendered them sensitive to the peptide (Figure 8G). G3BP1 is therefore dispensable for TAT-RasGAP317–326 to mediate its genotoxin-sensitizing effect on cancer cells.

Discussion

The evidence provided so far indicates that G3BP1 is not a (strong) RasGAP or fragment N2 binding partner and that TAT-RasGAP317–326 does not modulate any of the known G3BP1 functions. To unequivocally determine whether G3BP1 is needed for TAT-RasGAP317–326-mediated tumor sensitization, we used tumor cells in which G3BP1 was silenced and transformed MEFs from G3BP1 knock-out mice. Silencing G3BP1 using shRNA directed at the 3’ UTR of its mRNA resulted in 90% reduction in G3BP1 levels in U2OS cells (Figure 8A–B). This however did not prevent TAT-RasGAP317–326 from sensitizing the cells to cisplatin-induced death (Figure 8C). Earlier work has demonstrated that TAT-RasGAP317–326 does not sensitize non-cancer cells to cisplatin-induced apoptosis [2]. MEFs, which are non-cancer cells, were indeed not experiencing more cisplatin-induced death in presence of the peptide (Figure 8F). It is however possible to transform MEFs with the SV40 large T antigen [38]. We therefore expressed the large T antigen in MEFs via lentiviral infection (Figure 8D) and, as expected, this rendered them sensitive to the peptide (Figure 8G). G3BP1 is therefore dispensable for TAT-RasGAP317–326 to mediate its genotoxin-sensitizing effect on cancer cells.

Discussion

The evidence provided so far indicates that G3BP1 is not a (strong) RasGAP or fragment N2 binding partner and that TAT-RasGAP317–326 does not modulate any of the known G3BP1 functions. To unequivocally determine whether G3BP1 is needed for TAT-RasGAP317–326-mediated tumor sensitization, we used tumor cells in which G3BP1 was silenced and transformed MEFs from G3BP1 knock-out mice. Silencing G3BP1 using shRNA directed at the 3’ UTR of its mRNA resulted in 90% reduction in G3BP1 levels in U2OS cells (Figure 8A–B). This however did not prevent TAT-RasGAP317–326 from sensitizing the cells to cisplatin-induced death (Figure 8C). Earlier work has demonstrated that TAT-RasGAP317–326 does not sensitize non-cancer cells to cisplatin-induced apoptosis [2]. MEFs, which are non-cancer cells, were indeed not experiencing more cisplatin-induced death in presence of the peptide (Figure 8F). It is however possible to transform MEFs with the SV40 large T antigen [38]. We therefore expressed the large T antigen in MEFs via lentiviral infection (Figure 8D) and, as expected, this rendered them sensitive to the peptide (Figure 8G). G3BP1 is therefore dispensable for TAT-RasGAP317–326 to mediate its genotoxin-sensitizing effect on cancer cells.
reported in 1996 [8]. In this report, it was shown by Far Western blotting that a fusion protein between GST and the SH3 domain of RasGAP bound to G3BP1 from ER22 cell lysates and that this binding could be prevented by the addition of a peptide corresponding to the 317–326 RasGAP amino acid sequence. We were not able to reproduce these data using U2OS cell lysates and a recombinant histidine-tagged SH3 domain of RasGAP as a probe in the Far Western blotting procedure (data not shown). Moreover, in conditions where RasGAP and G3BP1 bound to known partners (i.e. p190 RhoGAP and USP10, respectively), no interaction between G3BP1 and RasGAP was detected (Figures 1, 2, 3). We used exponentially growing cells for these experiments as it was reported that G3BP1 does not interact with RasGAP in quiescent cells [9]. The results presented in Figures 1, 2, and 3 contrast with reports showing binding of RasGAP to G3BP1 by co-immunoprecipitation methods [8,9] and by using GST pull-down assays [10]. It has to be noted however that these studies did not provide controls excluding a non-specific binding to beads for example. The interaction between RasGAP and G3BP1 might be occurring in very specific situations. It has been reported that G3BP1 only binds to serum-stimulated cells [8,9] and only after specific cyclical periods of time following the stimulation: association detected 1 hour, 8 hours and 16 hours after serum addition but no association seen 10 minutes, 20 minutes, 2 hours, 4 hours following serum addition [9]. Whether such pattern of G3BP1-RasGAP association correlates with a known physiological cell cycle has not been defined.

Figure 7. TAT-RasGAP317–326 does not affect G3BP1 nuclear localization. A. HeLa cells were left untreated or treated for 18 hours with TAT (20 μM), TAT-RasGAP317–326 (20 or 40 μM). Immunocytochemistry against G3BP1 was then performed (the nuclei were stained in blue with the Hoechst 33342 dye) and confocal z-stacks were acquired. Three-dimensional images were then built with the imaris software. Representative examples of untreated and TAT-RasGAP317–326-treated cells are shown (scale bar: 5 μm). Alternatively, images were taken using conventional epifluorescence microscopy (scale bar: 10 μm). Panel B depicts representative examples and panel C shows the corresponding quantifications performed on 80 cells as described in the methods.

doi:10.1371/journal.pone.0029024.g007
We also tried to crosslink RasGAP to G3BP1 in U2OS cell lysates to visualize a 180 kDa RasGAP-G3BP1 complex, as previously shown [9], but our analysis failed to reveal such a complex (data not shown). We were therefore unable to reveal a binding between G3BP1 and either RasGAP or the SH3 domain-containing fragment N2 of RasGAP, even when we used techniques, conditions (e.g. cells incubated with serum) and cell lines (e.g. CCL39) used by others to report this interaction. A similar lack of interaction between RasGAP and G3BP1 has been reported earlier by another laboratory [12]. It is pertinent to mention here that RasGAP was not found in the proteins identified by mass spectrometry in the cellular material pulled down with an anti-RasGAP antibody (Hadi Khalil and Christian Widmann, unpublished results). The reverse was also true, i.e. G3BP1 was not identified by mass spectrometry in the cellular material pulled down with an anti-G3BP1 antibody (Sophie Martin and Jamal Tazi, unpublished results). The last, we took advantage of the recently crystallized structure of the NTF2 domain of human G3BP1 (PDB: http://www.pdb.org; #3QN) and the previously published structure of the RasGAP SH3 domain [41] to conduct molecular dynamics and docking simulations. This analysis failed to reveal a preferred binding site between the NTF2 domain of G3BP1 and the SH3 domain of RasGAP (Figure 9A). As a control, the ability of USP10 to dock to G3BP1 was also tested. Figure 9B shows that there was a preferred interaction conformation between these two proteins at sites demonstrated to interact in the crystal structure made of these two proteins [42]. In light of all our results, the possibility that RasGAP is not a genuine G3BP1 partner has to be considered.

**Figure 8. G3BP1 silencing does not affect TAT-RasGAP317–326-mediated sensitization of cancer cells to cisplatin-induced apoptosis.**

A, B. U2OS were infected with a non-target shRNA control vector or a G3BP1 shRNA-expressing lentivirus. After 72 hours, cells were analyzed by immunocytochemistry (panel A) and Western blotting (panel B) for the presence of G3BP1. C. Infected cells were incubated with 20 μM cisplatin and 20 μM TAT-RasGAP317–326 for 22 hours as indicated on the figure. Apoptosis was then scored. D. MEFs were infected or not with a large T antigen-expressing lentivirus and 3 days later the expression of the large T antigen was assayed by immunocytochemistry. E. G3BP1 expression in wild-type (WT) and G3BP1 knock-out (KO) SV40 large T antigen-transformed MEFs was assayed by Western blotting. F. Alternatively, these cells were incubated with increasing concentrations of cisplatin in the presence or in the absence of TAT-RasGAP317–326 for 22 hours. Apoptosis was then measured by scoring the number cells with pyknotic nuclei. G. Wild-type (WT) and G3BP1 knock-out (KO) SV40 large T-transformed MEFs were treated as in panel C. Asterisks indicate statistically significant differences; NS: not significant.

doi:10.1371/journal.pone.0029024.g008
Acknowledgments

We thank Yannick Krempp from the Cellular Imaging Facility of the University of Lausanne for 3D confocal image reconstruction, Dr. Véronique Leblanc and Dr. Bruno Tocqué for the gift of the hG3BP1.dn3 plasmid, Dr. Didier Trono for the gift of plasmid TRIP-PGK-IRESNEO-WHV, Dr. Olivier Staub for the gift of the 6xHis-Stag-mUSP10.dn3 plasmid and the anti-USP10 antibody, Dr. Michod for the gift of plasmid and Dr. Jeff Settlement for the gift of HA-rRhoGAP.prc.

Author Contributions

Conceived and designed the experiments: AA CW. Performed the experiments: AA AD. Analyzed the data: AA CW. Contributed reagents/materials/analysis tools: SM JT. Wrote the paper: AA CW. Discussed the results and edited the paper: AA AD SM JT CW.

References

1. Yang J-Y, Walicki J, Michod D, Dubuis G, Widmann C (2005) Impaired Akt activity down-modulation, caspase-3 activation, and apoptosis in cells expressing a caspase-resistant mutant of RasGAP at position 157. Mol Biol Cell 16: 3511–3520.
2. Michod D, Yang JY, Chen J, BenEy, Widmann C (2004) A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells. Oncogene 23: 8971–8978.
3. Michod D, Annibaldi A, Schaefer S, Dapples C, Rochat B, et al. (2009) Effect of RasGAP N2 fragment-derived peptide on tumor growth in mice. J Natl Cancer Inst 101: 828–832.
4. Pittet O, Petermann D, Michod D, Krueger T, Cheng C, et al. (2007) Effect of the TAT-RasGAP117–126 peptide on apoptosis of human malignant mesothelioma cells and fibroblasts exposed to n-nitro-tetrahydroxyphenyl-chlorin and light. J Photochem Photobiol B 88: 29–35.
5. Michod D, Widmann C (2007) TAT-RasGAP117–126 requires p53 and PUMA to sensitize tumor cells to genotoxins. Mol Cancer Res 5: 497–507.
6. Yu J, Wang Z, Kindeur K, Vogelstein B, Zhang L (2003) PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 100: 1931–1936.
7. Villunger A, Michalak EM, Coutla L, Mullauer F, Bock G, et al. (2003) p53- and drug-induced apoptotic responses mediated by Bcl3-only proteins puma and noxa. Science 302: 1036–1038.
8. Parker F, Maurier F, Delumeau I, Duchesne M, Faucher D, et al. (1996) A Ras-GTPase-activating protein SH3-domain-binding protein. Mol Cell Biol 16: 2561–2569.
9. Galbovi-F, Parker F, Chebli K, Maurier F, Labourier E, et al. (1998) A novel phosphorylation-dependent RNase activity of GAP-SH3 binding protein: a potential link between signal transduction and RNA stability. Mol Cell Biol 18: 3956–3965.
10. Kennedy D, French J, Guittard E, Ru K, Tocqué B, et al. (2001) Characterization of G3BPs: tissue specific expression, chromosomal localisation and rasGAP120 binding studies. J Cell Biochem 84: 173–187.
11. Stark LA, Dunlop MG (2005) Nuclear sequestration of RbE (p65) regulates NF-kB-driven transcription and apoptosis. Mol Cell Biol 25: 5965–6004.
12. Soscini C, Beato I, Draetta G (2001) Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease. Oncogene 20: 3869–3879.
13. Tourriere H, Chebli K, Zekri L, Courselaud B, Blanchard JM, et al. (2005) The RasGAP-associated endoribonuclease G3BP assembles stress granules. J Cell Biol 160: 823–831.
14. Anderson P, Kedersha N (2006) RNA granules. J Cell Biol 172: 803–808.
15. Ivanov PA, Nadezhdina ES (2006) Stress granules: RNP-containing cytoplasmic bodies arising in stress: structure and mechanism of organization. Molecular Biology 40: 937–944.
16. Buchanan JR, Parker R (2009) Eukaryotic stress granules: the ins and outs of translation. Mol Cell 36: 932–941.
17. Arimoto K, Fukuda H, Imaio-Osaki O, Gaito A, Takekawa M (2008) Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nat Cell Biol 10: 1324–1332.
18. Waldman T, Kindeur K, Vogelstein B (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187–5190.
19. Duffridge KB, Tang P, Huo HC, Lassig FM, Miller JH, et al. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7: 379–387.
20. Zekri L, Chebli K, Tourriere H, Nielsen FC, Hansen TV, et al. (2003) Control of fetal growth and neonatal survival by the RasGAP-associated endoribonuclease G3BP. J Biol Chem 278: 3511–3518.
21. Jordan M, Schallborn A, Wurm FM (1996) Transfacking mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 24: 596–601.
22. Yang J-Y, Widmann C (2001) Antitumorogenic signaling generated by caspase-induced cleavage of RasGAP. Mol Cell Biol 21: 5346–5358.
23. Gilmanshin R, VanBeek J, Callender R (1996) Study of the ribonuclease S-peptide/S-protein complex by means of Raman difference spectroscopy. Journal of Physical Chemistry 100: 16754–16760.
24. Barker MV, Gaymardlov T, Gorshkova I, Crouch R, Hu T, et al. (2003) Humanized docking system for assembly of targeting drug delivery complexes. J Control Release 89: 499–511.
25. Boulkroun S, Ruffieux-Daidie D, Vitagliano JJ, Poirot O, Charles RP, et al. (2008) Vasopressin-inducible ubiquitin-specific protease 10 increases ENaC cell surface expression by deubiquitylating and stabilizing sorting nexin 3. Am J Physiol Renal Physiol 295: F889–F900.

26. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463–8471.

27. Moran MF, Polakis P, McCormick F, Pawson T, Ellis C (1991) Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution, and activity of p21ras GTPase-activating protein. Mol Cell Biol 11: 1804–1812.

28. Settleman J, Albright CF, Foster LC, Weinberg RA (1992) Association between GTPase activators for Rho and Ras families. Nature 359: 153–154.

29. Tourniere H, Gallouzi IE, Chebli K, Capony J-P, Mouaikel J, et al. (2001) RasGAP-associated endoribonuclease G3BP: selective RNA degradation and phosphorylation-dependent localization. Mol Cell Biol 21: 7747–7760.

30. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, et al. (2003) Genomic targets of the human c-Myc protein. Genes Dev 17: 1115–1129.

31. Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976–990.

32. Egile A, Harris AW, Bouillet P, Cory S (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci U S A 101: 6164–6169.

33. Hemann MT, Bric A, Ternya-Feldstein J, Herbst A, Nilson JA, et al. (2005) Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 807–811.

34. Herrick DJ, Ross J (1994) The half-life of c-myc mRNA in growing and serum-stimulated cells: influence of the coding and 3′ untranslated regions and role of ribosome translocation. Mol Cell Biol 14: 2119–2128.

35. Yeilding NM, Rehman MT, Lee WM (1996) Identification of sequences in c-myc mRNA that regulate its steady-state levels. Mol Cell Biol 16: 3511–3522.

36. O’Connor L, Strasser A, O’Kelly LA, Hausmann G, Adams JM, et al. (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17: 384–395.

37. Ahuja D, Saez-Robles MT, Pipas JM (2005) SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24: 7729–7745.

38. Irvine K, Stirling R, Hume D, Kennedy D (2004) Rasputin, more promiscuous than ever: a review of G3BP. Int J Dev Biol 48: 1223–1231.

39. Ross B, Kristensen O, Favre D, Walicki J, Kastrup JS, et al. (2007) High resolution crystal structures of the p120 RasGAP SH3 domain-binding proteins, G3BPs, in human breast cancers. Histochem J 34: 223–231.

40. Li K, Zhao K, Ossareh-Nazari B, Da G, Dargemont C, et al. (2005) Structural basis for interaction between the Ubp3 deubiquitinating enzyme and its Bre5 cofactor. J Biol Chem 280: 29176–29185.